ESTIMABL2
2022
No Radioiodine Ablation vs. Low-Activity Radioiodine in Low-Risk Thyroid Cancer
In 730 patients with low-risk differentiated thyroid carcinoma after thyroidectomy, no radioiodine ablation was non-inferior to 1.1 GBq radioiodine plus rhTSH for event-free survival at 3 yr.
Result
- Absolute difference
- 0.3 points
The absolute difference is derived from the event rates.
Also reported: Non-inferiority demonstrated.
- Subtopic
- Differentiated thyroid cancer
- Design
- Open-label non-inferiority RCT, 3 yr
- Relevance
- Important: one of several pillars.
- Source
- Leboulleux S, et al. N Engl J Med. 2022;386(10):923-932.doi 10.1056/NEJMoa2111953
Discussion & critique
Practice-changing for low-risk DTC: radioiodine can be omitted entirely after total thyroidectomy in carefully selected patients.